The purpose of the study is to evaluate the use of an exercise phone application and a continuous glucose monitor and their impact on metabolic disease in adolescents with obesity, prediabetes and Type 2 diabetes. Participants will be asked to wear a continuous glucose monitor (Freestyle Libre) and if they are in the intervention group also participate in using an exercise phone application as well as have scheduled interval contact with a health professional in between scheduled clinic visits to assess how they are reaching their goals.
Patients will be recruited directly from the Childrens of Alabama pediatric endocrine clinic. Thirty patients who have obesity, prediabetes or Type 2 diabetes will be enrolled. During the enrollment phase, flyers will be posted in clinic and emails will be distributed to potential participants. Our study team will approach interested participants during their routine clinic visit. Consent will be obtained by study team during their endocrine clinic visit. Review of their medical records will be done and age, gender and race will be extracted from the medical record. A baseline visit with vital signs, blood work, a physical exam and nutritional counseling will be completed. Once enrolled, the patients will then be randomized.Within this pilot trial, we will randomize 15 adolescents/teenagers who either have obesity, prediabetes or Type 2 diabetes, to access to an exercise regimen and 15 adolescents to control intervention using a permuted block randomization scheme. The randomization scheme will contain 6 blocks of size 5 allowing for 30 randomized in the group with obesity, prediabetes and Type 2 diabetes. Those who are in the intervention group will then be given access to frequent telephone counseling to follow-up their nutrition and exercise goals, access to exercise application and accelerometer as described below. Follow-up will then be completed at 3 and 6 months with a physical exam, vital signs, blood draw. Intervention Group Access provided to exercise application Provided with Fitbit to wear and measure activity Weekly check-in with provider to determine how exercise goals have been that week. If unable to reach, we will text securely a clinic check-in and provide a healthy tip of the week. Meeting with nutrition at Baseline visit Continuous glucose monitor provided (plan to wear for 14 days during each month) Non-Intervention Group Meeting with nutrition at Baseline visit Continuous glucose monitor provided (plan to wear for 14 days at baseline visit, 3 month visit and 6 month visit)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
15 minute phone interview by health care provider to assess health goals set at clinic visits.
skin fold thickness
reliable estimate of subcutaneous fat at various sites of the body
Time frame: baseline
skin fold measurement
reliable estimate of subcutaneous fat at various sites of the body
Time frame: 3 month
skin fold measurement
reliable estimate of subcutaneous fat at various sites of the body
Time frame: 6 month
Body mass index
measure of body fat based on height and weight
Time frame: baseline
Body mass index
measure of body fat based on height and weight
Time frame: 3 month
Body Mass Index
measure of body fat based on height and weight
Time frame: 6 month
TNF-alpha
inflammatory marker in the blood
Time frame: baseline
TNF-alpha
inflammatory marker in the blood
Time frame: 3 months
TNF-alpha
inflammatory marker in the blood
Time frame: 6 months
IL-6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
inflammatory marker in the blood
Time frame: Baseline
IL-6
inflammatory marker in the blood
Time frame: 3 months
IL-6
inflammatory marker in the blood
Time frame: 6 months